relapsing-remitting multiple sclerosis
Neurology · 2007–2020
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ozanimod Treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS). | Mar 2020 | Deferred | input received MS Australia |
| natalizumab Clinically-definite relapsing-remitting multiple sclerosis (RRMS) in patients of all ages (removal of previous age restriction of 18 years and older). | Jul 2019 | Recommended with restriction | input received MS Australia · MS Research Australia |
| alemtuzumab Relapsing remitting multiple sclerosis (RRMS), specifically for up to two additional courses of treatment in patients who have experienced one or more relapses… | Nov 2018 | Not recommended | input received MS Research Australia |
| daclizumab Treatment of relapsing-remitting multiple sclerosis (RRMS) | Nov 2016 | Deferred | none received |
| natalizumab Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS) in ambulatory patients eighteen years of age or older as… | Nov 2007 | Recommended with restriction | no section in document |
| natalizumab Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS) in ambulatory patients eighteen years of age or older who… | Nov 2007 | Recommended with restriction | no section in document |
Who spoke
MS Research Australia · MS Australia
What the PBS pays
$43M in government benefit over 2024–25, across 42,564 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| natalizumab | $37.8M |
| ozanimod | $4.4M |
| alemtuzumab | $1.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.